Advances in Pharmaceutical Research:
From Lead Discovery to Drug Manufacturing- Spring 2003
Syllabus Schedule Links Course Homepage
Carl Decicco, Ph.D., Bristol-Myers Squibb
Identification of a Selectivity Determinant for Inhibition of Tumor Necrosis Factor-alpha Converting Enzyme by Comparative Modeling. Zelda R. Wasserman, ..., Carl P. Decicco Chemistry & Biology, 10 (3) (2003) pp. 215-223
Drugs (from the Dictionary of Drugs)
Etanercept, BAN
Synonym(s): Enbrel. TNF-001. TNFR-Fc
Chapman & Hall Number: GQO18-W
CAS Registry Number: 185243-69-0
Type of Compound Code(s): XA4750
General Statement: Recombinant tumour necrosis factor receptor Fc Fusion
protein
Biological Use/Importance: First specific anti-cytokine therapy approved for use in the treatment of rheumatoid arthritis
Development Status: Marketed drug. Approved 1998. Worldwide 69th best selling prescription drug ($0.76 bn, 2001) (Immunex) (Pharma Business) Other: Immunex Corp.
References:
Sorbera, L.A. etal., Drugs of the Future, 1998, 23, 951-954
Jarvis, B. etal., Drugs, 1999, 57, 945-966, (rev)
Moreland, L.W., Expert Opin. Invest. Drugs, 1999, 8, 1443-1451
Weinblatt, M.E. etal., N. Engl. J. Med., 1999, 340, 253-259, (clin trial)
Calin, A., J. Drug Eval. Rheumatol., 2001, 1, 13-40, (rev, pharmacol)
Entry Name: Infliximab
Synonym(s): Remicade, 9CI
Chapman & Hall Number: HOK36-D
CAS Registry Number: 170277-31-3
Type of Compound Code(s): XA4780
General Statement: Chimeric monoclonal antibody to tumour necrosis factor
Biological Use/Importance: Used in the treatment of Crohn's disease and rheumatoid arthritis
Development Status: Marketed drug. Approved for clinical use in the EU (1999). Worldwide 76th best selling prescription drug ($0.72 bn, 2001) (Johnson and Johnson) (Pharma Business)
References:
Van Hogezand, R.A. etal., Drugs, 1998, 56, 299-305, (pharmacol)
D'Haens, G. etal., Gastroenterology, 1999, 116, 22-28 1029-1034,
(pharmacol)
Moreland, L.W. etal., J. Rheumatol. Suppl., 1999, 57, 7-15, (rev)
Maini, R., Lancet, 1999, 354, 1932-1939, (pharmacol)
Markham, A. etal., Drugs, 2000, 59, 1341-1359, (rev)
This site is maintained by John.
Validate this document's xhmtl.
This site is best displayed in a recent browser such as NN 6.2, IE 6.0, Mozilla 1.0, or Opera 6.0. If you can read this message you probably need to upgrade your browser to one that supports web standards, or you might want to check that javascript is enabled.